These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 37294416)
1. Two Recombinant Bacteriocins, Rhamnosin and Lysostaphin, Show Synergistic Anticancer Activity Against Gemcitabine-Resistant Cholangiocarcinoma Cell Lines. Kerdkumthong K; Chanket W; Runsaeng P; Nanarong S; Songsurin K; Tantimetta P; Angsuthanasombat C; Aroonkesorn A; Obchoei S Probiotics Antimicrob Proteins; 2024 Jun; 16(3):713-725. PubMed ID: 37294416 [TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomics analysis reveals possible anticancer mechanisms of 5'-deoxy-5'-methylthioadenosine in cholangiocarcinoma cells. Kerdkumthong K; Nanarong S; Roytrakul S; Pitakpornpreecha T; Tantimetta P; Runsaeng P; Obchoei S PLoS One; 2024; 19(6):e0306060. PubMed ID: 38923999 [TBL] [Abstract][Full Text] [Related]
3. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway. Thongpon P; Intuyod K; Chomwong S; Pongking T; Klungsaeng S; Muisuk K; Charoenram N; Sitthirach C; Thanan R; Pinlaor P; Pinlaor S Sci Rep; 2024 Jul; 14(1):16059. PubMed ID: 38992159 [TBL] [Abstract][Full Text] [Related]
4. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317 [TBL] [Abstract][Full Text] [Related]
5. Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells. Pratummanee K; Kerdkumthong K; Roytrakul S; Tantimetta P; Runsaeng P; Saeheng S; Obchoei S Mol Med Rep; 2024 Nov; 30(5):. PubMed ID: 39239747 [TBL] [Abstract][Full Text] [Related]
6. Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells. Kitagawa K; Moriya K; Kaji K; Saikawa S; Sato S; Nishimura N; Namisaki T; Akahane T; Mitoro A; Yoshiji H Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066548 [TBL] [Abstract][Full Text] [Related]
7. Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo. Pongking T; Thongpon P; Intuyod K; Klungsaeng S; Thanan R; Chaidee A; Charoenram N; Kongsintaweesuk S; Sakonsinsiri C; Vaeteewoottacharn K; Pinlaor S; Pinlaor P BMC Complement Med Ther; 2024 Aug; 24(1):325. PubMed ID: 39215312 [TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis. Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545 [TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression. Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S Life Sci; 2022 May; 296():120427. PubMed ID: 35218764 [TBL] [Abstract][Full Text] [Related]
11. Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in Cholangiocarcinoma. Kerdkumthong K; Roytrakul S; Songsurin K; Pratummanee K; Runsaeng P; Obchoei S Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199357 [TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688 [TBL] [Abstract][Full Text] [Related]
13. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells. Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424 [TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941 [TBL] [Abstract][Full Text] [Related]
15. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma. Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603 [TBL] [Abstract][Full Text] [Related]
16. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines. Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372 [TBL] [Abstract][Full Text] [Related]
17. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models. Awasthi N; Darman L; Schwarz MA; Schwarz RE J Cell Mol Med; 2024 Sep; 28(17):e18585. PubMed ID: 39223878 [TBL] [Abstract][Full Text] [Related]